China Pharma (CPHI) Competitors $0.17 +0.01 (+9.16%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends CPHI vs. MRNS, PMCB, AWH, SLGL, WENA, IMNN, IPA, RLMD, CRVO, and KZIAShould you be buying China Pharma stock or one of its competitors? The main competitors of China Pharma include Marinus Pharmaceuticals (MRNS), PharmaCyte Biotech (PMCB), Aspira Women's Health (AWH), Sol-Gel Technologies (SLGL), ANEW Medical (WENA), Imunon (IMNN), ImmunoPrecise Antibodies (IPA), Relmada Therapeutics (RLMD), CervoMed (CRVO), and Kazia Therapeutics (KZIA). These companies are all part of the "pharmaceutical products" industry. China Pharma vs. Marinus Pharmaceuticals PharmaCyte Biotech Aspira Women's Health Sol-Gel Technologies ANEW Medical Imunon ImmunoPrecise Antibodies Relmada Therapeutics CervoMed Kazia Therapeutics Marinus Pharmaceuticals (NASDAQ:MRNS) and China Pharma (NYSE:CPHI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, risk, analyst recommendations, earnings, community ranking, dividends and institutional ownership. Which has more risk & volatility, MRNS or CPHI? Marinus Pharmaceuticals has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, China Pharma has a beta of 0.66, suggesting that its stock price is 34% less volatile than the S&P 500. Do analysts recommend MRNS or CPHI? Marinus Pharmaceuticals presently has a consensus target price of $4.79, indicating a potential upside of 1,980.75%. Given Marinus Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Marinus Pharmaceuticals is more favorable than China Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marinus Pharmaceuticals 0 Sell rating(s) 8 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.36China Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders believe in MRNS or CPHI? 98.8% of Marinus Pharmaceuticals shares are owned by institutional investors. 5.5% of Marinus Pharmaceuticals shares are owned by insiders. Comparatively, 17.3% of China Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer MRNS or CPHI? In the previous week, China Pharma had 1 more articles in the media than Marinus Pharmaceuticals. MarketBeat recorded 2 mentions for China Pharma and 1 mentions for Marinus Pharmaceuticals. China Pharma's average media sentiment score of 0.43 beat Marinus Pharmaceuticals' score of 0.00 indicating that China Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Marinus Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral China Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, MRNS or CPHI? China Pharma has lower revenue, but higher earnings than Marinus Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMarinus Pharmaceuticals$30.99M0.41-$141.40M-$2.47-0.09China Pharma$5.54M0.60-$3.08MN/AN/A Is MRNS or CPHI more profitable? China Pharma has a net margin of -85.56% compared to Marinus Pharmaceuticals' net margin of -446.48%. China Pharma's return on equity of -63.93% beat Marinus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Marinus Pharmaceuticals-446.48% -7,831.35% -120.74% China Pharma -85.56%-63.93%-31.42% Does the MarketBeat Community believe in MRNS or CPHI? Marinus Pharmaceuticals received 437 more outperform votes than China Pharma when rated by MarketBeat users. Likewise, 67.54% of users gave Marinus Pharmaceuticals an outperform vote while only 0.00% of users gave China Pharma an outperform vote. CompanyUnderperformOutperformMarinus PharmaceuticalsOutperform Votes43767.54% Underperform Votes21032.46% China PharmaOutperform VotesNo VotesUnderperform Votes76100.00% SummaryMarinus Pharmaceuticals beats China Pharma on 9 of the 17 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get China Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CPHI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CPHI vs. The Competition Export to ExcelMetricChina PharmaPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$3.35M$6.57B$5.14B$19.19BDividend YieldN/A3.00%5.09%3.62%P/E RatioN/A10.5990.1341.30Price / Sales0.60196.061,117.0917.51Price / CashN/A57.1643.1021.28Price / Book0.255.094.785.32Net Income-$3.08M$151.83M$120.31M$989.88M7 Day Performance-1.69%-2.14%-1.92%-3.54%1 Month Performance-9.47%-4.56%13.65%-4.73%1 Year Performance-68.76%8.87%28.34%11.57% China Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CPHIChina PharmaN/A$0.17+9.2%N/A-68.0%$3.35M$5.54M0.00231News CoverageGap UpHigh Trading VolumeMRNSMarinus Pharmaceuticals4.3176 of 5 stars$0.23-10.6%$4.79+1,937.3%-97.6%$12.96M$31.47M-0.10110Analyst ForecastNews CoveragePMCBPharmaCyte Biotech0.4217 of 5 stars$1.66-3.5%N/A-24.8%$12.75MN/A2.612Earnings ReportAWHAspira Women's Health1.2122 of 5 stars$0.76+0.7%$4.40+482.8%-69.7%$12.59M$9.15M-0.62110Analyst ForecastSLGLSol-Gel Technologies2.4245 of 5 stars$0.45-6.1%$5.00+1,010.6%-66.5%$12.54M$1.55M-1.3650WENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpIMNNImunon2.3547 of 5 stars$0.84-0.4%$20.50+2,337.0%+9.2%$12.20M$500,000.00-0.4533Analyst ForecastNews CoverageGap UpIPAImmunoPrecise Antibodies2.9227 of 5 stars$0.42+4.3%$5.00+1,089.1%-69.5%$12.12M$24.07M-0.5280News CoverageRLMDRelmada Therapeutics4.19 of 5 stars$0.40+7.7%$4.25+975.7%-87.7%$11.92MN/A-0.1310Gap DownHigh Trading VolumeCRVOCervoMed2.1768 of 5 stars$1.93+1.3%$42.00+2,081.8%-67.1%$11.88M$7.14M0.004Analyst DowngradeAnalyst RevisionHigh Trading VolumeKZIAKazia Therapeutics1.7282 of 5 stars$3.56+0.3%$20.00+461.8%-21.6%$11.85M$2.31M0.0012Gap Up Related Companies and Tools Related Companies Marinus Pharmaceuticals Competitors PharmaCyte Biotech Competitors Aspira Women's Health Competitors Sol-Gel Technologies Competitors ANEW Medical Competitors Imunon Competitors ImmunoPrecise Antibodies Competitors Relmada Therapeutics Competitors CervoMed Competitors Kazia Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:CPHI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding China Pharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share China Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
